ABCL Stock AbCellera Biologics Inc.
STRONG BUY US · NasdaqGSInsider interest and a near-term Phase 2 efficacy readout create a favorable catalyst setup.
Future value: $16.82 (+39.22%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Insider buying and Q3 clinical data catalyst.
- ▾Below 50-day MA (-0.72%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (76.1% of range) — strength
- ▸~39% upside to price target
Is ABCL a buy right now?
Trend: ABCL is trading below the 50-day average (-0.74%), RSI 54 — neutral momentum, with a 3-month return of +128.36%.
Valuation & quality: AbCellera Biologics Inc. trades on forward P/E -15.8, price-to-book 4.13; fundamentals show net margin -248.8%, return on equity -17.3%, revenue growth -76.3% year on year.
Analyst consensus: 11 analysts have a mean 12-month price target of $16.82 (+39.2% vs the last close; range $9.00 – $30.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 5) — Insider interest and a near-term Phase 2 efficacy readout create a favorable catalyst setup.
Computed from end-of-day data; not personal advice.
Our track record with ABCL
Our simulated $10,000 funds have traded ABCL 1 time — 1 of 1 closed trade profitable.
| Fund | Bought | Sold | Return |
|---|---|---|---|
| US High-risk | 2026-08-22 @ $11.14 | 2026-09-01 @ $11.35 · Monthly rebalance | +1.89% |
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -3.30% | +18.90% | +48.70% | +27.20% | -27.30% | +101.10% | +27.10% | -17.20% |
Fundamentals
Analyst price target
Technical signals
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Sector: Healthcare · Industry: Biotechnology · Canada · 562 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.